Development of an HPLC method for the radiochemical purity evaluation of [18F]fluoroestradiol
DOI:
https://doi.org/10.15392/bjrs.v7i2A.746Keywords:
18F-Fluoroestradiol, HPLC, Radiochemical Purity.Abstract
18F-Fluoroestradiol ([18F]FES), an estrogen analog, is a radiopharmaceutical used in Positron Emission Tomography (PET) that allows evaluating the tumor cell receptor profile and the best therapy strategy, the staging, the prognosis and the response to therapy in several breast cancer cases. As there is not any pharmacopoeia’s monograph of [18F]FES to standardize its quality control criteria, this work presents a new HPLC’s method to perform the [18F]FES radiochemical purity. A liquid chromatograph was used with radioactivity and ultraviolet detectors. Three concentrations of fluoroestradiol standard solution were used along the test. Their retention time was compared to its relative radiolabelled analogue to confirm its identity. Several mobile phases with acetonitrile and two mobile phase flows were tested to optimize the runs. Peaks symmetry, retention time, theoretical plates and resolution were analyzed to choose the best conditions. The mean retention time of both standard Fluoroestradiol and [18F]FES solutions were the same, demonstrating that [18F]FES formulation did not interfere with [18F]FES analysis. The best conditions were 1.2 mL/min and isocratic 40% V/V acetonitrile in water, which gave [18F]FES peak resolution greater than 6 and symmetry factor of 1. Thus, the developed method is ready to be validated and implemented in [18F]FES quality control routine in CDTN/Brazil.Downloads
References
MINISTÉRIO DA SAÚDE. INCA – Instituto Nacional do Câncer José Alencar Gomes da Silva. Estimativa 2016: Incidência de Câncer no Brasil. Rio de Janeiro: INCA, p. 32-34. 2015. Available at: <http://www.inca.gov.br/estimativa/2016/estimativa-2016-v11.pdf>. Last accessed: 23 Jun. 2016.
MINISTÉRIO DA SAÚDE. INCA – Instituto Nacional do Câncer José Alencar Gomes da Silva. Estimativa 2014: Incidência de Câncer no Brasil. Rio de Janeiro: INCA, p. 34-35. 2014. Available at: <http://www.saude.sp.gov.br/resources/ses/perfil/gestor/homepage/outros-destaques/ estimativa-de-incidencia-de-cancer-2014/estimativa_cancer_24042014.pdf>. Last accessed: 10 Dec. 2014.
RODRIGUES, K. E.; CAMARGO, B. Diagnóstico precoce do câncer infantil: responsabilidade de todos. Rev Assoc Med Bras, v. 49, p. 29-34, 2003.
JACOBSON, O.; CHEN, X. PET Designated Fluoride-18 Production and Chemistry. Curr Top Med Chem, v. 10, p. 1048-1059, 2010.
FLANAGAN, F. L.; DEHDASHTI, F.; SIEGEL, B. A. PET in Breast Cancer. Semin Nucl Med, v. 28, p. 290-302, 1998.
SURTI, S. Radionuclide Methods and Instrumentation for Breast Cancer Detection and Diagnosis. Semin Nucl Med, v. 43, p. 271-280, 2013.
CHAN, J. M.; LEE, H. J.; GOO, J. M.; LEE, H. Y.; LEE, J. J.; CHUNG, J. K.; IM, J. G. False Positive and False Negative FDG-PET Scans in Various Thoracic Diseases. Korean J Radiol, v. 7, p. 57-69, 2006.
LINDEN, H. M. L.; DEHDASHTI, F. Novel Methods and Tracers for Breast Cancer Imaging. Semin Nucl Med, v. 43, p. 324-329, 2013.
SUNDARARAJAN, L.; LINDEN, H. M.; LINK, J. M.; KROHN, K. A.; MANKOFF, D. A. 18F-Fluoroestradiol. Semin Nucl Med, v. 37, p. 470-476, 2007.
ANVISA – Agência Nacional de Vigilância Sanitária. Farmacopeia Brasileira. 5th ed. Brasília, Brazil: Anvisa, v. 1, p. 374. 2010. Available at: <http://www.anvisa.gov.br/hotsite/cd_ farmacopeia/pdf/volume2.pdf>. Last accessed: 13 Sep. 2017.
KNOTT, K. E.; GRÄTZ, D.; HÜBNER, S.; JÜTTLER, S.; ZANKL, C.; MÜLLER, M. Simplified and automatic one-pot synthesis of 16α-[18F]fluoroestradiol without high-performance liquid chromatography purification. J Label Compd Radiopharm, v. 54, p. 749-753, 2011.
AGILENT TECHNOLOGIES. The LC Handbook: Guide to LC Columns and Method Development. USA: Agilent Technologies, 2016. Available at: <https://www.agilent.com/cs/ library/primers/Public/LC-Handbook-Complete-2.pdf>. Last accessed: 13 Sep. 2017.
UNITED STATES PHAMACOPEIAL CONVENTION. USP/NF 2016 – United States Phamacopeia/National Formulary. 39th ed., v. 1. Rockville, USA: United States Pharmacopeia, 2016.
KUMAR, P.; MERCER, J.; DOERKSON, C.; TONKIN, K.; MCEWAN, A. J. B. Clinical production, stability studies and PET imaging with 16-α-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients. J Pharm Pharm Sci, v. 10, p. 256s-265s, 2007.
MORI, T.; KASAMATSU, S.; MOSDZIANOWSKI, C.; WELCH, M. J.; YONEKURA, Y.; FUJIBAYASHI, Y. Automatic synthesis of 16α-[18F]fluoro-17β-estradiol using a cassette-type [18F]fluorodeoxyglucose synthesizer. Nucl Med Biol, v. 33, p. 281-286, 2006.
COUNCIL OF EUROPE. European pharmacopoeia. 7th ed., v. 1. Strasbourg, France: Council of Europe, 2016.
DIXIT, M.; SHI, J.; WEI, L.; AFARI, G.; BHATTACHARYYA, S. Synthesis of Clinical-Grade [18F]-Fluoroestradiol as a Surrogate PET Biomarker for the Evaluation of Estrogen Receptor-Targeting Therapeutic Drug. Int J Mol Imaging, v. 2013, article ID 278607, 2013.
Published
Issue
Section
Categories
License
Copyright (c) 2021 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
How to Cite
